In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38

References

• Allen TM, Austin GA, Chonn A, et al. (1991). Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1061:56–64
   PubMed Web of Science ®Google Scholar
• Bansal T, Awasthi A, Jaggi M, et al. (2008). Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN38, in rat plasma and bile samples: application to pharmacokinetic studies. Talanta 76:1015–21
   PubMed Web of Science ®Google Scholar
• Caliceti P, Veronese FM. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261–77
   PubMed Web of Science ®Google Scholar
• Chabot GG. (1997). Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245–59
   PubMed Web of Science ®Google Scholar
• Dodds HM, Hanrahan J, Rivory LP. (2001). The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables. Anticancer Drug Des 16:239–46
   PubMedGoogle Scholar
• Ebrahimnejad P, Dinarvand R, Jafari MR, et al. (2011). Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN38. Int J Pharm 406:122–7
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–61
   PubMed Web of Science ®Google Scholar
• Giovanella BC, Stehlin JS, Wall ME, et al. (1989). DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science (New York, N.Y.) 246:1046–8
   PubMed Web of Science ®Google Scholar
• Guo S, Zhang X, Gan L, et al. (2010). Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2). J Pharm Pharmacol 62:973–84
   PubMed Web of Science ®Google Scholar
• Jaxel C, Kohn KW, Wani MC, et al. (1989). Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465–9
   PubMed Web of Science ®Google Scholar
• Koizumi F, Kitagawa M, Negishi T, et al. (2006). Novel SN38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048–56
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Goel S, Wheler J, et al. (2012). Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118:6144–51
   PubMed Web of Science ®Google Scholar
• Lokiec F, Canal P, Gay C, et al. (1995). Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 36:79–82
   PubMed Web of Science ®Google Scholar
• Ma MK, McLeod HL. (2003). Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–9
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, Marsh S, Karlsson MO, et al. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246–53
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, van Alphen RJ, Verweij J, et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–94
   PubMed Web of Science ®Google Scholar
• Meyer-Losic F, Nicolazzi C, Quinonero J, et al. (2008). DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin Cancer Res 14:2145–53
   PubMed Web of Science ®Google Scholar
• Midgley RS, Kerr DJ, Flaherty KT, et al. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 18:2025–9
   PubMed Web of Science ®Google Scholar
• Monnin KA, Bronstein IB, Gaffney DK, et al. (1999). Elevations of DNA topoisormerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol 30:384–91
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Patnaik A, Papadopoulos KP, Tolcher AW, et al. (2013). Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol 71:1499–506
   PubMed Web of Science ®Google Scholar
• Ramesh M, Ahlawat P, Srinivas NR. (2010). Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr 24:104–23
   PubMed Web of Science ®Google Scholar
• Rivory LP, Chatelut E, Canal P, et al. (1994). Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN38 in patients. Cancer Res 54:6330–3
   PubMed Web of Science ®Google Scholar
• Salmaso S, Bersani S, Scomparin A, et al. (2010). Supramolecular bioconjugates for protein and small drug delivery. Isr J Chem 50:160–74
   Web of Science ®Google Scholar
• Sapra P, Zhao H, Mehlig M, et al. (2008). Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888–96
   PubMed Web of Science ®Google Scholar
• Satoh T, Yasui H, Muro K, et al. (2013). Pharmacokinetic assessment of irinotecan, SN38, and SN38-glucuronide: a substudy of the FIRIS study. Anticancer Res 33:3845–53
   PubMed Web of Science ®Google Scholar
• Serrano AG, Perez-Gil J. (2006). Protein–lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids 141:105–18
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Matsuzaki T, Matsushita M, et al. (1988). Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71–4
   PubMed Web of Science ®Google Scholar
• Wang JC. (1996). DNA topoisomerases. Annu Rev Biochem 65:635–92
   PubMed Web of Science ®Google Scholar
• Wang JC. (2002). Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–40
   PubMed Web of Science ®Google Scholar
• Xiang Q-y, Wang M-t, Chen F, et al. (2007). Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 30:519–25
   PubMed Web of Science ®Google Scholar
• Zhang JA, Xuan T, Parmar M, et al. (2004). Development and characterization of a novel liposome-based formulation of SN38. Int J Pharm 270:93–107
   PubMed Web of Science ®Google Scholar
• Zhang X, Gan Y, Gan L, et al. (2008). Pegylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 60:1077–87
   PubMed Web of Science ®Google Scholar
• Zhao H, Rubio B, Sapra P, et al. (2008). Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 19:849–59
   PubMed Web of Science ®Google Scholar